Mineralys Therapeutics, Inc. (MLYS) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
150 N. RADNOR CHESTER ROAD RADNOR, PA 19087 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 198,187,000 | 236,567,000 | |||
| Cash and cash equivalent | 114,091,000 | 49,304,000 | |||
| Short-term investments | 84,096,000 | 187,263,000 | |||
| Deferred costs | 400,000 | ||||
| Other undisclosed current assets | 6,764,000 | 12,536,000 | |||
| Total current assets: | 205,351,000 | 249,103,000 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 53,000 | ||||
| Long-term investments and receivables | 2,482,000 | ||||
| Long-term investments | 2,482,000 | ||||
| Other noncurrent assets | 499,000 | 51,000 | |||
| Total noncurrent assets: | 552,000 | 2,533,000 | |||
| TOTAL ASSETS: | 205,903,000 | 251,636,000 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 14,646,000 | 10,482,000 | |||
| Accounts payable | 479,000 | 601,000 | |||
| Accrued liabilities | 14,167,000 | 9,881,000 | |||
| Total current liabilities: | 14,646,000 | 10,482,000 | |||
| Noncurrent Liabilities | |||||
| Total liabilities: | 14,646,000 | 10,482,000 | |||
| Equity | |||||
| Equity, attributable to parent | 191,257,000 | 241,154,000 | |||
| Common stock | 5,000 | 4,000 | |||
| Additional paid in capital | 493,770,000 | 365,858,000 | |||
| Accumulated deficit | (302,518,000) | (124,708,000) | |||
| Total equity: | 191,257,000 | 241,154,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 205,903,000 | 251,636,000 | |||
Income Statement (P&L) (USD)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Operating expenses | (192,403,000) | (84,657,000) | ||
| Operating loss: | (192,403,000) | (84,657,000) | ||
| Nonoperating income | 14,593,000 | 12,759,000 | ||
| Net loss available to common stockholders, diluted: | (177,810,000) | (71,898,000) | ||
Comprehensive Income (USD)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Net loss: | (177,810,000) | (71,898,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (177,810,000) | (71,898,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.